Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion

Inclusion Criteria:

1. 18-75 years old;
2. Non-small cell lung cancer with pleural metastasis confirmed by histopathology orcytology;
3. ECOG score 0-1;
4. Cardiopulmonary function can tolerate painless thoracoscopic examination;
5. Patients who underwent medical thoracoscopy for pleural effusion at first diagnosisand underwent medical thoracoscopy cryotherapy at the same time of biopsy were alsoincluded in the study. Non-small cell lung cancer was confirmed by pathologicalresults;
6. All subjects or their guardians must sign the informed consent before entering thestudy.

Exclusion Criteria:

1. Expected survival <2 months;
2. Hemoglobin <110g/L, white blood cell count <3×109/L, neutrophil <2.0×109/L, platelet <100×109/L;
3. severe cardiac insufficiency, abnormal liver and kidney function (blood test resultsof transaminase and creatinine > 1.5 times the normal upper limit);
4. have received chemotherapy or anti-angiogenic drugs (such as bevacizumab, endu,anlotinib, etc.);
5. History of radiotherapy;
6. history of intrathoracic local treatment;
7. multiple serous cavity effusion, or bilateral pleural effusion;
8. patients allergic to erythromycin;
9. the lung cannot be reopened.